Safety profile of oral and intravenous moxifloxacin: Cumulative data from clinical trials and postmarketing studies
- 1 July 2004
- journal article
- review article
- Published by Elsevier in Clinical Therapeutics
- Vol. 26 (7) , 940-950
- https://doi.org/10.1016/s0149-2918(04)90170-1
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Efficacy and Tolerability of Moxifloxacin in 2338 Patients with Acute Exacerbation of Chronic BronchitisClinical Drug Investigation, 2003
- Adverse Drug Reactions Related to the Use of Fluoroquinolone AntimicrobialsDrug Safety, 2003
- Possible Gatifloxacin-Induced HypoglycemiaAnnals of Pharmacotherapy, 2002
- Rapid Resolution of Symptoms with Moxifloxacin Therapy in 7223 Patients with Acute Exacerbation of Chronic BronchitisClinical Drug Investigation, 2002
- Fluoroquinolone Adverse Effects and Drug InteractionsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2001
- New Milestones Achieved in Fluoroquinolone SafetyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2001
- Acute Eosinophilic Hepatitis from TrovafloxacinNew England Journal of Medicine, 2000
- Safety of the new fluoroquinolones compared with ciprofloxacin.Journal of Chemotherapy, 2000
- Comparative Tolerability of the Newer Fluoroquinolone AntibacterialsDrug Safety, 1999
- Temafloxacin Syndrome: Review of 95 CasesClinical Infectious Diseases, 1994